focus -WSS

focus

author：hotspot 2025-09-30 02:09:13 - browse：5

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Readout Newsletter: BridgeBio, Akero, and human embryo models

leisure time

WSS

Police still searching for prisoner who escaped from NYC hospital

Readout Newsletter: BridgeBio, Akero, and human embryo models

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Harvard's David Sinclair gets blowback over aging

Why Talkspace is targeting Medicare, a tricky market

Police still searching for prisoner who escaped from NYC hospital

hotspot

focus

hotspot

How one medical school became remarkably diverse

Stem cell biologist probes earliest stages of human development

Medicare details structure of new drug price negotiation program

Medicare drug price negotiation hearing pits pharma v Biden admin

Hepatitis C has a cure — but many Americans still lack access to it

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

In Memoriam: Notable people who died in 2023

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Novavax promises a turnaround & Lilly roils the obesity market

Harvard's David Sinclair gets blowback over aging

leisure time

A new approach to psychiatric drug development

Wegovy’s successful heart trial raises vital question about weight loss

Florida health officials providing scant details on measles cases

South Korea throws huge K

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Maui's cultural, historic landmarks damaged in the devastating wildfires

entertainment

explore

leisure time

Wikipedia